House Dems host “The Things We’ll Never Know: A Science Fair of Canceled Grants”

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

In the face of the unknown, two cancer center leaders discuss planning for the future, recovering from setbacks, and holding on to what they still have.

September 12, 2025

Vol.51 No.33

By Claire Marie Porter, Jacquelyn Cobb and Paul Goldberg

Guest Editorial

Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines

Look at where our understanding of cancer was two, five, 10, 15, 20, or more years ago and then consider what has happened over the past two decades. We finally realized how more complex the problem of cancer is—more than any of us imagined.

As House committee gives NIH a small raise, cancer groups hope to maintain bipartisan support

The U.S. House Appropriations Committee has voted along party lines passing a bill that maintains current funding levels for NIH and NCI as part of its Fiscal Year 2026 Labor, HHS, Education and Related Agencies spending bill.

September 12, 2025

Vol.51 No.33

By Claire Marie Porter

In Brief

Mark Foundation for Cancer Research, Samuel Waxman Cancer Research Foundation establish Aging & Cancer Institute

The Mark Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation announced they will combine in a first-of-its-kind transaction in cancer philanthropy to launch the Samuel Waxman Institute for Aging & Cancer.

September 12, 2025

Vol.51 No.33

In Brief

Wistar Institute receives $17M NIH grant for personalized HIV cure research

The Wistar Institute has received an NIH granted, five-year $17 million research award to launch iCure Consortium to develop individualized “cure regimens” for HIV.

September 12, 2025

Vol.51 No.33

In Brief

2025 Lasker awards announced

Top row (left to right): Dirk Görlich, Steven L. McKnight, Michael J. Welsh.Bottom row (left to right): Jesús (Tito) González, Paul A. Negulescu, Lucy ShapiroThe 2025 Albert Lasker Basic Medical Research Award honors went to two scientists for discoveries that exposed the structures and functions of low-complexity domains within protein sequences.

September 12, 2025

Vol.51 No.33

House Dems host “The Things We’ll Never Know: A Science Fair of Canceled Grants”

YOU MAY BE INTERESTED IN

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines

As House committee gives NIH a small raise, cancer groups hope to maintain bipartisan support

Mark Foundation for Cancer Research, Samuel Waxman Cancer Research Foundation establish Aging & Cancer Institute

Wistar Institute receives $17M NIH grant for personalized HIV cure research

2025 Lasker awards announced

Renew today!

Subscriber content

Never miss an issue!

Login

House Dems host “The Things We’ll Never Know: A Science Fair of Canceled Grants”

YOU MAY BE INTERESTED IN

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

Reflections of a cancer scientistMaintaining the pace of novel technologies will lead to more efficient and less toxic medicines

As House committee gives NIH a small raise, cancer groups hope to maintain bipartisan support

Mark Foundation for Cancer Research, Samuel Waxman Cancer Research Foundation establish Aging & Cancer Institute

Wistar Institute receives $17M NIH grant for personalized HIV cure research

2025 Lasker awards announced

Never miss an issue!

Login

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines